Skip to content

SANGAMO THERAPEUTICS, INC

SGMO

CIK 0001001233

← back to feed
Revenue (TTM)
$26.77M
−31.6% YoY Q1 May 2026
Net Income (TTM)
−$116.51M
−25.5% YoY Q1 May 2026
EPS Diluted (TTM)
−$0.41
+10.2% YoY Q1 May 2026
Gross Margin
—
Q1 May 2026
Operating Margin
-429.6%
Q1 May 2026
Net Margin
-435.3%
Q1 May 2026
Free Cash Flow (TTM)
−$170.61M
Q1 May 2026
Cash
$27.59M
Q1 May 2026
Total Debt
—
Q1 May 2026
Shares Outstanding
414.29M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings